Robin Cohen
Chief Commercial Officer, Emergex
Robin has worked in the pharmaceutical industry for 25 years in a number of senior commercial and business development roles with both UK and Global experience of bringing new therapeutics to market through to late lifecycle management of medicines. Robin began his career selling medicines to the NHS and progressed though more senior leadership roles, including commercial lead for Janssen Cilag’s Infectious Diseases team and working as part of the EMEA strategic marketing group.
Robin has worked across many therapy areas with particular emphasis on Oncology, Haematology and Infectious Disease fields with Johnson and Johnson, where he was leading Infectious Diseases for the UK and Global Director of Business Development for Infectious Diseases and Hepatology. At the start of 2021, Robin moved to join Emergex Vaccines – a clinical stage biotech, based near Oxford developing novel T Cell priming adaptive vaccines to tackle some of the world’s most impactful pathogens. Emergex have 2 vaccine candidates in Phase 1 clinical trials and Robins role is to set and lead the commercial strategy for Emergex. Robin is currently Chief Commercial Officer at Emergex.
